Tag: SPYRAL

Landmark SPYRAL HTN-OFF MED Pivotal Trial Shows Superiority for Renal Denervation in Patients with High Blood Pressure Compared to Sham Procedure

Coronary/Structural Heart by 0 comments

ACC.20/WCC: Study Finds Significant Blood Pressure Reductions Achieved with RDN in Absence of Anti-Hypertensive Medication  Medtronic Receives FDA “Breakthrough Device Designation” for Symplicity Spyral™ Renal Denervation System DUBLIN, March 29, 2020 (GLOBE NEWSWIRE) —  Medtronic plc (NYSE:MDT), the global leader in medical technology, […]

Continue Reading →

Medtronic Begins New Pilot Study as Part of SPYRAL HTN Clinical Program for Renal Denervation in Hypertension Patients

Coronary/Structural Heart Peripheral/Endo by 0 comments

SPYRAL DYSTAL Study to Evaluate the Effects of RDN Using Fewer, Targeted Ablations to Achieve Meaningful Blood Pressure Reductions DUBLIN, Feb. 04, 2020 (GLOBE NEWSWIRE) —  Medtronic plc (NYSE:MDT) today announced it will begin enrollment in a pilot study evaluating the safety […]

Continue Reading →